Transaction DateRecipientSharesTypePriceValue
24th February 2021Target N V Biotech75,000Open or private purchase$11.48$860,835.00
23rd February 2021Target N V Biotech235,004Open or private purchase$11.29$2,653,030.66
18th February 2021Target N V Biotech1,185,770Open or private purchase$12.65$14,999,990.50
1st February 2021Target N V Biotech80,000Open or private purchase$11.69$935,344.00
29th January 2021Target N V Biotech80,000Open or private purchase$11.94$955,000.00
10th December 2020Target N V Biotech170,000Open or private purchase$8.18$1,391,416.00
10th December 2020Target N V Biotech150,000Open or private purchase$8.39$1,258,425.00
9th December 2020Target N V Biotech125,000Open or private purchase$8.62$1,077,600.00
10th November 2020Target N V Biotech80,000Open or private purchase$9.16$732,472.00
9th November 2020Target N V Biotech80,000Open or private purchase$9.05$724,144.00
Molecular Templates
Molecular Templates logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Molecular Templates, Inc. was founded on October 17, 2001 and is headquartered in Austin, TX. The company utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies.

Ticker: MTEM
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1183765
Employees: 168
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $28 M (0%)
Marketable Securities, Current: $63 M (59%)
Other Assets, Current: $160 Th (-67%)
Assets, Current: $108 M (-22%)
Property, Plant and Equipment, Net: $20 M (0%)
Other Assets, Noncurrent: $5 M (3%)
Assets: $142 M (-18%)
Accounts Payable, Current: $2 M (13%)
Accrued Liabilities, Current: $14 M (0%)
Liabilities, Current: $41 M (15%)
Long-term Debt, Excluding Current Maturities: $15 M (400%)
Other Liabilities, Noncurrent: $1 M (4%)
Liabilities: $87 M (21%)
Common Stock, Value, Issued: $46 Th (0%)
Common Stock, Shares, Issued: $46 M (0%)
Additional Paid in Capital, Common Stock: $273 M (2%)
Retained Earnings (Accumulated Deficit): $217 M (32%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $172 Th (855%)
Stockholders' Equity (Parent): $56 M (0%)
Liabilities and Equity: $142 M (-18%)
Research and Development: $30 M (-40%)
General and Administrative Expenses: $6 M (-46%)
Operating Income/Loss: $30 M (-42%)